TauRx' Alzheimer drug to provide greater profit for GENTING 3182 GENTING BERHAD
The completion of clinical trials of an Alzheimer’s drug by Genting Bhd’s unit TauRx Pharmaceuticals Ltd will provide greater profitability for the company.
KUALA LUMPUR: The completion of clinical trials of an Alzheimer's drug by Genting Bhd's unit TauRx Pharmaceuticals Ltd will provide greater profitability for the company.
RHB Research said Genting had completed the Phase 3 clinical trial (LUCIDITY) of its Alzheimer's treatment, HMTM, and was moving towards regulatory submission.
"We are positive on this development, as it marks a step forward for TauRx to potentially bring HMTM to the market, providing greater visibility to its path to profitability," it said in a note.
The research house said while Genting did not point out positive top-line results for the LUCIDITY trial, it put HMTM in a favourable spot to receive the necessary regulatory approvals.
TauRx will provide further data analysis at the 35th Global Conference of Alzheimer's Disease International on June 9.
"If the trial shows positive top-line results, this could pave the way to accelerated regulatory review and approvals, and the subsequent market launch of the drug, which could be by late 2023, according to TauRx's chief operating officer.
"We note that prior to the release of LUCIDITY's initial data, the United Kingdom (UK) Medicines & Healthcare products Regulatory Agency (MHRA) granted TauRx an 'Innovation Passport' on 18 May – this is the first stage of the Innovative Licencing and Access Pathway or ILAP, which is intended to accelerate development and approval times, facilitating access to new products," it said.
RHB Research has maintained its earning forecast on Genting as it believes that street has yet to factor TauRx into the company's valuations.
"We make no changes to our earnings forecasts and SOP target price of MYR6.37, which includes a 14 per cent ESG discount.
"We chose to not include TauRx in Genting's SOP for now, pending greater clarity on its valuations. Nevertheless, we maintain our Buy call on Genting," it added.
https://www.nst.com.my/business/2022/06/801566/taurx-alzheimer-drug-provide-greater-profit-genting
Singapore Investment
-
-
-
-
-
$1M in Gold Bars in Just ONE Drawer9 hours ago
-
-
-
-
-
随心笔:错15 hours ago
-
-
-
-
-
-
-
-
-
-
Portfolio Update1 day ago
-
-
-
A Sign Of Market High?1 day ago
-
-
-
-
-
-
-
-
Manulife Goal 2025 (II)3 days ago
-
-
-
-
-
-
-
-
Cory Diary : Reits Experience4 days ago
-
-
-
-
-
-
-
-
Got money, how to invest?6 days ago
-
-
-
-
-
-
-
-
Month of August 20251 week ago
-
August 2025 Updates1 week ago
-
Portfolio Update August 20251 week ago
-
-
-
-
Portfolio (Aug 31, 2025)1 week ago
-
Portfolio (Aug 31, 2025)1 week ago
-
-
-
There is No TOMORROW1 week ago
-
-
LongBridge2 weeks ago
-
-
-
Why SGD ETFs Deserve a Second Look2 weeks ago
-
Decoupling2 weeks ago
-
-
-
-
-
-
-
-
Why Buy Always Drop? (Vice versa)3 weeks ago
-
Been a while!4 weeks ago
-
-
-
Endowus Promotion TnC5 weeks ago
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Clarity3 months ago
-
Selling HRnet and Fiverr3 months ago
-
-
FAQ on Quantitative Investing Part 24 months ago
-
-
-
Crossing the 300k Mark [in a volatile period]5 months ago
-
-
-
-
ETF vs Mutual Fund: Which is Better?7 months ago
-
-
-
-
Arigato Everyone! A Decade of Blogging!8 months ago
-
Top 10 Highlights of 20248 months ago
-
-
Union Square Residences10 months ago
-
-
-
STI ETF11 months ago
-
-
-
Unibet Casino Bonus Codes 20241 year ago
-
-
-
-
-
Monthly IBKR Update – June 20241 year ago
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Monthly Summary of November 20231 year ago
-
Migration of website1 year ago
-
-
-
-
-
-
Hello SP Group, I'm Back!2 years ago
-
-
-
A New Light2 years ago
-
-
-
-
-
2022 Thoughts, Hello 2023!2 years ago
-
Series of Defaults for Maple Finance2 years ago
-
Takeaways from “Sea Change”2 years ago
-
Greed is Coming Back2 years ago
-
-
-
-
-
-
-
-
What is Overemployment3 years ago
-
Terra Hill Condo (former Flynn Park)3 years ago
-
Alibaba VS Tencent: The Battle Royale3 years ago
-
-
-
-
-
-
-
-
-
-
-
-
-